前列腺癌实时自适应SBRT后6个月多参数MRI反应与PSA动力学相关
回顾性单中心研究纳入72例接受MRI-LINAC引导SBRT局灶剂量强化且未用雄激素剥夺治疗的局限性前列腺癌患者,6个月时mpMRI完全缓解(CR)者PSA下降更显著、PSA50比例更高、PSA≤1.0 ng/mL比例更高。6个月mpMRI反应与PSA动力学相关,可用于评估DIL局部肿瘤反应。
要点
- 6个月mpMRI CR率为51.4%(37/72),与更大幅PSA下降相关。
- mpMRI CR者PSA50达100.0%,非CR者82.9%(p=0.010)。
- mpMRI CR者PSA≤1.0 ng/mL为45.9%,非CR者11.4%(p=0.001)。
核心结论
- 6个月mpMRI反应与治疗后PSA动力学相关,后者与重要临床结局相关。
- mpMRI可用于SBRT后评估DIL局部肿瘤反应,DIL是大多数复发发生部位。
研究设计与样本
- 回顾性单中心研究,纳入72例局限性前列腺癌患者。
- 患者接受MRI-LINAC引导SBRT局灶剂量强化,未行雄激素剥夺治疗。
- SBRT后6个月行mpMRI和PSA随访,mpMRI CR定义为DWI和DCE-MRI无残留病灶。
主要发现
- 6个月时37例(51.4%)达到mpMRI CR。
- mpMRI CR者PSA下降81.8%,非CR者66.1%(p<0.001)。
- mpMRI CR者PSA50为100.0%,非CR者82.9%(p=0.010)。
- mpMRI CR者PSA≤1.0 ng/mL为45.9%,非CR者11.4%(p=0.001)。
- 10例6个月未达mpMRI CR但后续MRI随访(中位13个月)者,DIL缩小30.0%或消退70.0%。
关键数值与推荐
- mpMRI CR定义:DWI和DCE-MRI无残留病灶。
- PSA50定义:PSA下降≥50.0%。
- PSA≤1.0 ng/mL为评估指标之一。
临床怎么用
- SBRT后6个月mpMRI可用于评估DIL局部肿瘤反应。
- mpMRI反应可与PSA动力学联合解读,辅助判断疗效。
- 未达6个月mpMRI CR者仍需进一步MRI随访观察。
局限性
- 回顾性单中心设计。
- 样本量72例。
- 未行雄激素剥夺治疗,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Focal dose intensification strategies targeting the dominant intra-prostatic lesion (DIL) improve outcomes of patients with prostate cancer. The purpose was to determine whether the 6-month multiparametric (mp)MRI response of the DIL is associated with post-treatment prostate-specific antigen (PSA) kinetics after MRI linear accelerator (LINAC) guided stereotactic body radiotherapy (SBRT) with focal dose intensification. METHODS: Retrospective, single-center study including 72 patients with localized prostate cancer treated with MRI-LINAC SBRT with focal dose intensification and without androgen deprivation therapy. Patients were followed up at 6 months after SBRT with mpMRI and PSA. mpMRI complete response (CR) was defined as no residual lesion on diffusion-weighted imaging and dynamic contrast-enhanced MRI. This was correlated with PSA responses including PSA reduction (%), PSA reduction ≥ 50.0% (PSA50), and PSA ≤ 1.0 ng/mL. RESULTS: mpMRI CR was achieved in 37 patients (51.4%) at 6 months. Patients with mpMRI CR had greater PSA reduction (81.8% vs 66.1%, p < 0.001), and more commonly had PSA50 (100.0% vs 82.9%, p = 0.010) and PSA ≤ 1.0 ng/mL (45.9% vs 11.4%, p = 0.001) compared to those without mpMRI CR. In 10 patients without 6-month mpMRI CR but had further MRI follow-up (median 13 months), DILs either further decreased in size (30.0%) or resolved (70.0%). CONCLUSION: Initial 6-month mpMRI response correlates with PSA kinetics, which is associated with important clinical outcomes. mpMRI can be used for post-SBRT evaluation to gauge local tumor response of the DIL, where most recurrences occur.
引用
- Woo S, Becker AS, Vargas HA, et al. Multiparametric MRI assessment of 6-month Post-Treatment response following Real-Time adaptive stereotactic body radiotherapy for prostate cancer: Correlation with Post-Treatment PSA kinetics. Radiother Oncol. 2026. PMID: 41802704. doi:10.1016/j.radonc.2026.111478
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。